One proven test will help you breathe easier.
RiskReveal® is a genomic test that has been rigorously validated to accurately gauge the risk of lung cancer recurrence after surgery and is the only test with prospective randomized data that predict a benefit from additional, post-operative treatment for high-risk patients.
Sometimes surgery is just the first step toward cure.
After surgery, early-stage non-small cell lung cancer returns in 30–50% of patients. RiskReveal accurately assesses the degree of risk for each individual patient, based on the molecular biology of each individual tumor. It is the only test that has randomized predictive data demonstrating a benefit from post-operative therapy for high-risk patients.
Approximately
53,000
patients are diagnosed with early-stage non-small cell lung cancer (NSCLC) each year.¹
Despite complete surgical resection,
30 to 50%
of early-stage patients will not survive five years.
With RiskReveal:
96%
of high-risk patients who received post-operative chemotherapy remained alive and disease-free at 2-5 years.²
1 National Institutes of Health, National Cancer Institute. (2023). Cancer Stat Facts: Lung Cancer. Surveillance, Epidemiology, and End Results Program.
https://seer.cancer.gov/statfacts/html/lungb.html
2 The AIM-HIGH study presented a prespecified interim analysis at 2 years. A non-randomized study from 2021 demonstrated that 97.0% of RiskReveal high-risk patients who were treated with adjuvant chemotherapy remained alive and disease free at 5 years.
RiskReveal provides critical information to doctors and to patients.
For medical professionals
RiskReveal helps you guide clinical decisions in time frames that matter. It is the only prognostic test for early-stage lung cancer with prospective randomized clinical trial data that definitively demonstrate the test’s predictive efficacy in identifying patients who benefit from adjuvant chemotherapy following surgical resection.
For Patients
Knowing the likelihood of your cancer’s recurrence is the first step to preventing it. RiskReveal helps determine who needs to take an additional step toward their cure and provides peace of mind to those who don’t.
Robert McKenna, MD
Thoracic Surgeon, John Wayne Cancer Institute
I think that RiskReveal is practice-changing and very important for discussions that we have with patients. I like giving patients enough information about their situation, and the pros and cons of additional treatment after their operation, so they’re loaded with the information to help them decide if they want adjuvant treatment.
Alejandro Calvo, MD
Medical Oncologist, Kettering Cancer Center
In medical oncology, data is very important, especially reliable data. The prospective randomized validation of RiskReveal gives me confidence to use chemotherapy in the subset of patients that need it. And it allows the patients also to feel more confident taking some risks by knowing the benefit they obtain.
Edgardo Santos, MD, FACP
Florida Precision Oncology
“The integration of testing for chemotherapy selection by RiskReveal will enable oncologists to optimize treatment post-surgery. In my opinion, this test closes the few remaining gaps that we currently face in deciding adjuvant therapy for early-stage adenocarcinoma of the lung. With these results, I feel confident initiating chemotherapy for RiskReveal high-risk patients I see in my practice.”
